FDA fast-tracking of a therapy involving Precision BioSciences, Arrowhead Pharmaceuticals, and Gilead Sciences began on July 1, 2025.
1 report, 0 independent
Updated Jul 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA fast-tracking of a therapy involving Precision BioSciences, Arrowhead Pharmaceuticals, and Gilead Sciences began on July 1, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Arrowhead Pharmaceuticals issued a press release from its offices in Pasadena on June 23, 2025.Sub-event
- FDA fast-tracked a therapy on July 1, 2025, involving the listed companies.
Keep exploring
The entities involved
- FDA
-
Precision BioSciences
American gene editing company
-
Arrowhead Pharmaceuticals
biopharmaceutical company
Nothing else this week.
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
Related events
- Experimental therapies require approval from the FDA.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- The FDA requested additional clinical data from Unicycive Therapeutics.
Coverage
Newest first; wire copies grouped- Unknown outlet